Form 4: Gabriele Cerrone Increases Stake in OKYO Pharma

Director and 10% owner Gabriele M. Cerrone acquired 300,000 shares of OKYO Pharma Ltd common stock at $1.72 per share.

Summary

• Gabriele M. Cerrone, a Director and 10% owner of OKYO Pharma Ltd, purchased 300,000 shares of common stock.
• The transaction occurred on June 8, 2026, at a price of $1.72 per share.
• Following this acquisition, the reporting person beneficially owns 10,826,416 shares indirectly via Panetta Partners Limited.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as significant insider buying typically reflects confidence in the company's strategic direction.

Positives

• Insider confidence is demonstrated by the purchase of 300,000 shares by a major shareholder and director.
• The acquisition increases the alignment between the director and the company's long-term performance.

Negatives

• None identified in this filing.

Risks

• Concentration of ownership in the hands of a single entity or individual may influence corporate decision-making.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal of management's belief in the company's valuation and future prospects within the competitive biotechnology sector.

Comparison to Industry Standards

• Insider buying activity is consistent with standard corporate governance practices where directors maintain significant equity stakes.

Related Party Transactions

• The shares are held indirectly via Panetta Partners Limited, an entity associated with the reporting person.

Stakeholder Impact

• Shareholders may interpret this purchase as a sign of stability and confidence from company leadership.

Key Dates

Keywords

OKYO Pharma, Insider Trading, Form 4, Gabriele Cerrone, Equity Acquisition